Pulse Pressure and Post-epidural Fetal Heart Rate Changes
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02565485 |
|
Recruitment Status :
Completed
First Posted : October 1, 2015
Results First Posted : June 8, 2018
Last Update Posted : July 9, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Fetus or Neonate Affected by Maternal Epidural Anesthesia During Labor and Delivery | Drug: Lactated Ringer's | Not Applicable |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 276 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Prevention |
| Official Title: | Pulse Pressure-guided IV Fluid Preload to Prevent Post-epidural Fetal Heart Rate (FHR) Changes: a Randomized Controlled Trial |
| Actual Study Start Date : | September 1, 2015 |
| Actual Primary Completion Date : | November 1, 2016 |
| Actual Study Completion Date : | November 1, 2016 |
| Arm | Intervention/treatment |
|---|---|
|
No Intervention: Standard IV Preload
Patients in this arm will receive 500mL of Lactated Ringer's solution, which is the standard IV fluid preload used on Labor and Delivery at MetroHealth Medical Center
|
|
|
Experimental: Volume Replacement IV Preload
Patients in this arm will receive 1500mL of Lactated Ringer's solution
|
Drug: Lactated Ringer's
1500 cc of IV Fluid (crystalloid) used for preload prior to epidural administration in the treatment arm. Control arm receives 500 cc.
Other Name: Ringer's Lactate |
- Incidence of New-onset Category II or III Fetal Heart Rate Tracings [ Time Frame: First 60 minutes following epidural placement ]Each fetal heart rate tracing was evaluated in 15 min increments from the completion of epidural placement and initial dose administration. ACOG Category I, II, and III was assigned to each 15 min increment.
- New Onset Hypotension (>20% Decrease in Systolic and/or Diastolic Blood Pressure) [ Time Frame: First 60 minutes following epidural placement ]
- Interventions to Correct Maternal Hypotension or Fetal Heart Rate Abnormalities (Position Change, Supplemental Oxygen, Vasopressor Support, Emergent Operative Delivery) [ Time Frame: First 60 minutes following epidural placement ]
- Adverse Events (Pulmonary Edema) [ Time Frame: Duration of intrapartum course ]Pulmonary edema occurring after preload bolus through delivery was considered an adverse event.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Singleton pregnancy with gestational age ≥ 35 weeks
- Admission for delivery
- Age 18 or older
- Desires neuraxial analgesia in labor
- No exclusion criteria
- Maternal pulse pressure < 45 mmHg on admission (verified by repeat blood pressure)
- Category 1 FHT on admission/prior to epidural placement
- Epidural placement within 6 hours of admission to Labor and Delivery
Exclusion Criteria:
- Multiple gestation
- Intrauterine growth restriction
- Hypertensive disorders (gestational hypertension, chronic hypertension, and preeclampsia/eclampsia)
- Gestational or pregestational diabetes mellitus
- Substance abuse
- Intrauterine fetal demise
- Congenital or chromosomal fetal abnormalities
- Category II or III FHR tracing on admission to L&D (pre-epidural)
- Contraindication to neuraxial aesthesia (e.g. thrombocytopenia)
- Maternal cardiomyopathy, congenital heart disease, active pulmonary edema or any other underlying maternal cardiopulmonary condition that increases the risk of pulmonary edema
- Maternal renal insufficiency (serum creatinine > 1.0)
- Maternal hypotension (as defined in secondary outcomes below) prior to epidural placement
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02565485
| United States, Ohio | |
| MetroHealth Medical Center | |
| Cleveland, Ohio, United States, 44109 | |
| Principal Investigator: | Justin R Lappen, MD | MetroHealth Medical Center |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Edward Chien, MD, Professor, Reproductive Biology, MetroHealth Medical Center |
| ClinicalTrials.gov Identifier: | NCT02565485 |
| Other Study ID Numbers: |
IRB15-00366 |
| First Posted: | October 1, 2015 Key Record Dates |
| Results First Posted: | June 8, 2018 |
| Last Update Posted: | July 9, 2018 |
| Last Verified: | June 2018 |
|
pulse pressure fetal heart rate epidural analgesia hypotension |
preload fluid bolus central hypovolemia |

